tetano
Editor, Senior Moderator
Pathog Dis. 2014 Jul 28. doi: 10.1111/2049-632X.12206. [Epub ahead of print]
An H1-H3 Chimeric Influenza Virosome Confers Complete Protection against Lethal Challenge with PR8 (H1N1) and X47 (H3N2) Viruses in Mice.
Abdoli A1, Soleimanjahi H, Tavassoti Kheiri M, Jamali A, Mazaheri V, Abdollahpour Alitappeh M.
Author information
Abstract
Annual health threats and economic damages caused by influenza virus are still a main concern of the World Health Organization and other health departments all over the world. An influenza virosome is a highly efficient immunomodulating carrier mimicking the natural antigen presentation pathway and has shown an excellent tolerability profile due to its biocompatibility and purity. The major purpose of this study was to construct a new chimeric virosome influenza vaccine containing hemagglutinin (HA) and neuraminidase (NA) proteins derived from the A/PR/8/1934 (H1N1) (PR8) and A/X/47 (H3N2) (X47) viruses, and to evaluate its efficacy as a vaccine candidate in mice. A single intramuscular vaccination with the chimeric virosomes provided complete protection against lethal challenge with the PR8 and X47 viruses. The chimeric virosomes induced high IgG antibody responses as well as hemagglutination inhibition (HAI) titers. HAI titers following the chimeric virosome vaccination were at the same level as the whole inactivated influenza vaccine. Mice immunized with the chimeric virosomes displayed considerably less weight loss and exhibited significantly reduced viral load in their lungs compared to the controls. The chimeric virosomes can be used as an innovative vaccine formulation to confer protection against a broad range of influenza viruses. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
KEYWORDS:
Influenza virus; Protection; Vaccination; Virosome
PMID:
25066138
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25066138
An H1-H3 Chimeric Influenza Virosome Confers Complete Protection against Lethal Challenge with PR8 (H1N1) and X47 (H3N2) Viruses in Mice.
Abdoli A1, Soleimanjahi H, Tavassoti Kheiri M, Jamali A, Mazaheri V, Abdollahpour Alitappeh M.
Author information
Abstract
Annual health threats and economic damages caused by influenza virus are still a main concern of the World Health Organization and other health departments all over the world. An influenza virosome is a highly efficient immunomodulating carrier mimicking the natural antigen presentation pathway and has shown an excellent tolerability profile due to its biocompatibility and purity. The major purpose of this study was to construct a new chimeric virosome influenza vaccine containing hemagglutinin (HA) and neuraminidase (NA) proteins derived from the A/PR/8/1934 (H1N1) (PR8) and A/X/47 (H3N2) (X47) viruses, and to evaluate its efficacy as a vaccine candidate in mice. A single intramuscular vaccination with the chimeric virosomes provided complete protection against lethal challenge with the PR8 and X47 viruses. The chimeric virosomes induced high IgG antibody responses as well as hemagglutination inhibition (HAI) titers. HAI titers following the chimeric virosome vaccination were at the same level as the whole inactivated influenza vaccine. Mice immunized with the chimeric virosomes displayed considerably less weight loss and exhibited significantly reduced viral load in their lungs compared to the controls. The chimeric virosomes can be used as an innovative vaccine formulation to confer protection against a broad range of influenza viruses. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
KEYWORDS:
Influenza virus; Protection; Vaccination; Virosome
PMID:
25066138
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25066138